

05/12/2025

To
BSE Limited,
Dept. of Corporate Services,
Floor 25, PJ Towers, Dalal Street,
Mumbai-400001

Scrip Code: 526445

Dear Sir/Madam,

Sub: Intimation of Board Meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, further to our earlier outcome dated 14th November, 2025, the Meeting of the Board of Directors of the Company, which was earlier postponed due to the requirement of additional information and clarifications by our Audit Committee, will now be held on, Thursday, December 11, 2025, inter alia, to consider and approve the following:


1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and Half year ended September 30, 2025, along with the Limited Review Report by Statutory Auditors.
2. To take note of resignation of Ms. Lakshmiprabha Kasiraman (DIN: 02885912) from the Position of Director on the Board.
3. Any other business with the permission of the Chair

In accordance with the Company's Code of Conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of Insider trading Regulations, 2015, the trading window for dealing in the securities of the Company is closed for the designated persons from October 01, 2025, till the expiry of 48 hours from the time the said financial results are made public.

This is for your information and record.

Thanking you,

**Yours faithfully,
For Indrayani Biotech Limited**



**Ramya Ravi
Company Secretary and Compliance Officer**